Tiziana Life Sciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.01.21	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibod (GlobeNewswire)
18.12.20	Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus (GlobeNewswire)
17.12.20	Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM (GlobeNewswire)
01.12.20	Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET (GlobeNewswire)
18.11.20	Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing (GlobeNewswire)
11.11.20	Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease (GlobeNewswire)
02.11.20	Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody (GlobeNewswire)
27.10.20	Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) (GlobeNewswire)
02.10.20	Tiziana Life Sciences Plc (the "Company") - Result of General Meeting (GlobeNewswire)
25.09.20	Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report (GlobeNewswire)
21.09.20	Tiziana Life Sciences plc: Publication of Research Note (GlobeNewswire)
17.09.20	Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil (GlobeNewswire)
16.09.20	Pre-market Movers In Healthcare Sector: TLSA, APDN, AVEO, TNXP, ETON… (RTTNews)
16.09.20	Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in Specie (GlobeNewswire)
15.09.20	Pre-market Movers In Healthcare Sector: NVUS, MRNS, ABIO, LPCN, CLRB, VXRT… (RTTNews)
28.08.20	Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement (GlobeNewswire)
27.08.20	Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview (GlobeNewswire)
24.08.20	Pre-market Movers In Healthcare Sector: SONN, ADMA, THMO, LMNL, KMDA... (RTTNews)
24.08.20	Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases (GlobeNewswire)
21.08.20	Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers (GlobeNewswire)
20.08.20	Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term (GlobeNewswire)
18.08.20	Pre-market Movers In Healthcare Sector: NMTR, TLSA, PTN, SRNE... (RTTNews)
18.08.20	Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease (GlobeNewswire)
11.08.20	Tiziana Life Sciences to Present at BTIG’s Virtual Biotechnology Conference (GlobeNewswire)
05.08.20	Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering (GlobeNewswire)
04.08.20	Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients (GlobeNewswire)
03.08.20	Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million (GlobeNewswire)
31.07.20	Tiziana Life Sciences plc: Total Voting Rights (GlobeNewswire)
31.07.20	Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients (GlobeNewswire)
30.07.20	Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM (GlobeNewswire)
30.07.20	Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020 (GlobeNewswire)
24.07.20	Exercise of Warrants and Issue of Equity and Total Voting Rights (GlobeNewswire)
20.07.20	Tiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment (GlobeNewswire)
17.07.20	ACIU'S Alzheimer's Vaccine Study Chugs Along, LCI Up On Distribution Deal, TLSA Hits New High (RTTNews)
16.07.20	Results of Annual General Meeting (GlobeNewswire)
16.07.20	Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy (GlobeNewswire)
15.07.20	Tiziana Life Sciences plc Change to ADS Ratio - Updated (GlobeNewswire)
15.07.20	Tiziana Life Sciences plc Change to ADS Ratio (GlobeNewswire)
10.07.20	Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report (GlobeNewswire)
18.06.20	Tiziana Life Sciences PLC Directorate Change (GlobeNewswire)
27.04.20	Tiziana Files Patent On Combination Of NP-ACT D With Anti-IL-6R (RTTNews)
11.03.20	Stock Alert: Tiziana Speeds Up Coronavirus Treatment; Stock Up 311.88% (RTTNews)
11.10.19	5 Top Losers In Healthcare Sector (AKTX, COCP, AUPH…) (RTTNews)
26.04.19	7 Top Gainers In Healthcare Sector (TLSA, SWAV, CPRX...) (RTTNews)
16.04.19	AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019? (RTTNews)
20.03.19	Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH (GlobeNewswire)
19.12.18	TLRY Teams Up With Novartis, TLSA To Report Data In Q2, RARX Marches Ahead (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Tiziana Life Sciences PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten